Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Feb 23:14:1163991.
doi: 10.3389/fphar.2023.1163991. eCollection 2023.

Editorial: Cannabidiol treatment in neurotherapeutic interventions, volume II

Gustavo Gonzalez-Cuevas  1   2 , Francisco Navarrete  3   4   5 , Maria S Garcia-Gutierrez  3   4   5 , Giordano de Guglielmo  6 , Jorge Manzanares  3   4   5
Affiliations
Editorial

Editorial: Cannabidiol treatment in neurotherapeutic interventions, volume II

Gustavo Gonzalez-Cuevas et al. Front Pharmacol. .
No abstract available

Keywords: Alzheimer’s disease; CBD; Parkinson’s diseae; acetaminophen, mood disorders, autism spectrum disorder (ASD); cannabidiol; neurotherapeutics; psychiatric disorders.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Cannabidiol treatment in neurotherapeutic interventions, volume II

References

    1. Aishworiya R., Valica T., Hagerman R., Restrepo B. (2022). An update on psychopharmacological treatment of autism spectrum disorder. Neurother. J. Am. Soc. Exp. Neurother. 19 (1), 248–262. 10.1007/s13311-022-01183-1 - DOI - PMC - PubMed
    1. Alemany S., Avella-García C., Liew Z., García-Esteban R., Inoue K., Cadman T., et al. (2021). Prenatal and postnatal exposure to acetaminophen in relation to autism spectrum and attention-deficit and hyperactivity symptoms in childhood: Meta-analysis in six European population-based cohorts. Eur. J. Epidemiol. 36 (10), 993–1004. 10.1007/s10654-021-00754-4 - DOI - PMC - PubMed
    1. Babayeva M., Assefa H., Basu P., Loewy Z. (2022). Autism and associated disorders: Cannabis as a potential therapy. Front. Biosci. (Elite Ed. 14 (1), 1. 10.31083/j.fbe1401001 - DOI - PubMed
    1. Balachandran P., Elsohly M., Hill K. P. (2021). Cannabidiol interactions with medications, illicit substances, and alcohol: A comprehensive review. J. General Intern. Med. 36 (7), 2074–2084. 10.1007/s11606-020-06504-8 - DOI - PMC - PubMed
    1. Brignell A., Marraffa C., Williams K., May T. (2022). Memantine for autism spectrum disorder. Cochrane database Syst. Rev. 8 (8), CD013845. 10.1002/14651858.CD013845.pub2 - DOI - PMC - PubMed

Publication types

LinkOut - more resources